查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974019

癌症免疫療法市場分析及預測（至2035年）：類型、產品、技術、應用、最終用戶、模式、階段、功能、解決方案

Cancer Immunotherapy Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Mode, Stage, Functionality, Solutions
出版日期: | 出版商: Global Insight Services | 英文 356 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

癌症免疫療法市場預計將從2024年的2,286億美元成長到2034年的5,423億美元，複合年成長率約為9%。癌症免疫療法市場涵蓋利用和增強免疫系統自身攻擊癌症能力的治療方法，例如單株抗體、查核點抑制劑和癌症疫苗。該市場的成長動力來自技術進步、癌症發病率上升以及人們對個人化醫療日益成長的關注。創新正推動人們致力於提高療效、減少副作用並提供持久的治療效果，同時專注於研究和臨床試驗，以拓展治療方法應用範圍。

癌症免疫療法市場正經歷強勁成長，這主要得益於個人化醫療和標靶治療的進步。單株抗體憑藉其靶向癌細胞的特異性和高效性，在療效方面佔主導地位。查核點抑制劑能夠增強免疫系統對抗癌症的能力，其療效也排名第二。過繼性細胞移植療法，包括CAR-T細胞療法，正作為變革性療法嶄露頭角，並具有巨大的未來應用潛力。疫苗，尤其是治療性癌症疫苗，因其在預防癌症復發方面的潛力而備受關注。細胞激素雖然並非主導因素，但仍在促進免疫反應中發揮輔助作用。生物標記和伴隨診斷的整合正在提高治療的精確度，並推動市場進一步擴張。持續的研發投入和策略合作對於在這個充滿活力的環境中探索新機會、確保永續成長和創新至關重要。

市場區隔
類型 單株抗體、查核點抑制劑、癌症疫苗、細胞激素、過繼性細胞療法、溶瘤病毒療法、雙特異性抗體、免疫查核點調節劑
產品 治療性抗體、免疫系統調節劑、細胞療法、查核點阻斷劑、癌症疫苗、溶瘤病毒、細胞激素
科技 基因編輯、CRISPR、CAR-T細胞療法、TCR療法、單株抗體技術、奈米技術、雙特異性抗體技術
目的 肺癌、乳癌、大腸癌、黑色素瘤、攝護腺癌、白血病、淋巴瘤
最終用戶 醫院、癌症研究機構、診所、生物製藥公司、學術研究機構
模式 靜脈注射、口服、皮下注射、肌肉注射
步 臨床試驗、商業化、臨床前階段。
功能 免疫活化、免疫抑制、免疫調節
解決方案 個人化免疫療法、聯合治療、標靶治療

市場概況：

癌症免疫療法市場充滿活力，創新定價策略和新治療方法的推出推動了市場佔有率的顯著變化。新產品的不斷上市正在重塑競爭格局，並創造一個有利於成長和發展的環境。各公司正利用其先進的研發能力進行策略性佈局，以抓住新的機會。旨在提高治療效果和擴大市場的策略聯盟和夥伴關係關係進一步加速了這一發展勢頭。在這種競爭環境下，主要企業正在進行嚴格的標竿分析，以保持其競爭優勢。監管影響至關重要，嚴格的指導方針界定了市場准入和永續性。全球法規結構各不相同，北美和歐洲制定的嚴格標準影響全球標準。亞太地區正崛起為一個充滿潛力的市場，這得益於有利的監管改革和不斷成長的醫療保健投資。競爭與監管的相互作用正在塑造癌症免疫療法市場的發展軌跡，為創新和成長提供了沃土。

主要趨勢和促進因素：

癌症免疫療法市場正經歷強勁成長，這主要得益於技術進步和研發投入的增加。關鍵趨勢包括：針對個別患者情況量身定做的個人化免疫療法的開發，從而改善治療效果；聯合治療的興起，透過整合多種治療方法來增強療效，也是一大趨勢；此外，對腫瘤微環境的深入了解正在推動標靶治療的創新；監管支持的加強和核准流程的加速正在加速新治療方法進入市場；全球癌症發病率的上升以及對更有效治療方法的未滿足需求等因素也推動了市場成長；此外，醫療服務提供者和患者對免疫療法的認知度和接受度不斷提高，也促進了市場發展。新興市場醫療基礎設施正在發展，對先進療法的需求不斷成長，這些地區蘊藏著許多機會。投資最尖端科技並尋求策略合作的公司將能夠更好地掌握這些趨勢，預計癌症免疫療法市場將持續成長。

壓制與挑戰：

癌症免疫療法市場面臨許多重大限制與挑戰。其中一項主要挑戰是治療費用高昂。這不僅限制了許多患者的治療機會，也給醫療保健系統帶來了沉重的經濟負擔。這些治療方法之所以價格昂貴，是因為它們需要大量的研發投入。監管障礙也是一大挑戰。新型免疫療法的嚴格核准流程會延緩其上市時間並增加成本。此外，癌症免疫療法的作用機制複雜，難以預測患者的治療反應，導致治療結果有差異。另一項挑戰是用於患者篩選的生物標記數量有限。這限制了識別最有可能從特定治療方法中獲益的患者的能力，從而降低了療法的有效性。此外，該市場還面臨來自更成熟、更廣泛接受的傳統癌症療法（如化療和放射線治療）的競爭。最後，需要提高大眾和專業人士的認知度。對免疫療法潛在益處的認知不足會阻礙其推廣應用和融入標準治療方案。

目錄

第1章：摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 查核點抑制劑
    • 癌症疫苗
    • 細胞激素
    • 過繼性細胞療法
    • 溶瘤病毒療法
    • 雙特異性抗體
    • 免疫查核點調節劑
  • 市場規模及預測：依產品分類
    • 治療性抗體
    • 免疫系統調節劑
    • 細胞療法
    • 查核點抑制
    • 癌症疫苗
    • 溶瘤病毒
    • 細胞激素
  • 市場規模及預測：依技術分類
    • 基因編輯
    • CRISPR
    • CAR-T細胞療法
    • TCR療法
    • 單株抗體技術
    • 奈米科技
    • 雙特異性抗體技術
  • 市場規模及預測：依應用領域分類
    • 肺癌
    • 乳癌
    • 結腸癌
    • 黑色素瘤
    • 攝護腺癌
    • 白血病
    • 淋巴瘤
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究機構
    • 診所
    • 生物製藥公司
    • 學術研究機構
  • 市場規模及預測：依模式
    • 靜脈注射
    • 口服
    • 皮下注射
    • 肌肉內注射
  • 市場規模及預測：依階段分類
    • 臨床試驗
    • 市售
    • 臨床前階段
  • 市場規模及預測：依功能分類
    • 免疫活化
    • 免疫抑制
    • 免疫調節
  • 市場規模及預測：依解決方案分類
    • 個人化免疫療法
    • 聯合治療
    • 標靶治療

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Adaptimmune Therapeutics
  • Immunocore
  • Iovance Biotherapeutics
  • Fate Therapeutics
  • Kite Pharma
  • Jounce Therapeutics
  • Replimune Group
  • Compugen
  • Agenus
  • OncoSec Medical
  • CureVac
  • Neon Therapeutics
  • BioNTech
  • Tessa Therapeutics
  • Argenx

第9章 關於我們

簡介目錄
Product Code: GIS33693

Cancer Immunotherapy Market is anticipated to expand from $228.6 billion in 2024 to $542.3 billion by 2034, growing at a CAGR of approximately 9%. The Cancer Immunotherapy Market encompasses treatments that harness and enhance the innate powers of the immune system to combat cancer, including monoclonal antibodies, checkpoint inhibitors, and cancer vaccines. This market is driven by technological advancements, a rising prevalence of cancer, and an increasing focus on personalized medicine. Innovations aim to improve efficacy, reduce side effects, and offer durable responses, with a strong emphasis on research and clinical trials to expand therapeutic applications.

The Cancer Immunotherapy Market is experiencing robust growth, propelled by advancements in personalized medicine and targeted therapies. The monoclonal antibodies segment leads in performance, owing to their specificity and effectiveness in targeting cancer cells. Checkpoint inhibitors, which enhance the immune system's ability to fight cancer, are also gaining prominence as the second highest performing segment. Adoptive cell transfer therapies, including CAR-T cell therapies, are emerging as a transformative approach, offering substantial promise for future applications. Vaccines, particularly therapeutic cancer vaccines, are witnessing increased interest due to their potential to prevent cancer recurrence. Cytokines, although less dominant, continue to play a supportive role in boosting immune responses. The integration of biomarkers and companion diagnostics is enhancing treatment precision, driving further market expansion. Continuous research and development, coupled with strategic collaborations, are pivotal in unlocking new opportunities within this dynamic landscape, ensuring sustained growth and innovation.

Market Segmentation
TypeMonoclonal Antibodies, Checkpoint Inhibitors, Cancer Vaccines, Cytokines, Adoptive Cell Therapy, Oncolytic Virus Therapy, Bispecific Antibodies, Immune Checkpoint Modulators
ProductTherapeutic Antibodies, Immune System Modulators, Cell Therapies, Checkpoint Blockade, Cancer Vaccines, Oncolytic Viruses, Cytokines
TechnologyGene Editing, CRISPR, CAR-T Cell Therapy, TCR Therapy, Monoclonal Antibody Technology, Nanotechnology, Bi-specific Antibody Technology
ApplicationLung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Leukemia, Lymphoma
End UserHospitals, Cancer Research Institutes, Clinics, Biopharmaceutical Companies, Academic and Research Institutes
ModeIntravenous, Oral, Subcutaneous, Intramuscular
StageClinical Trials, Commercialized, Preclinical
FunctionalityImmune Activation, Immune Suppression, Immune Modulation
SolutionsPersonalized Immunotherapy, Combination Therapies, Targeted Therapy

Market Snapshot:

The Cancer Immunotherapy Market is witnessing a dynamic landscape with a significant shift in market share, driven by innovative pricing strategies and the introduction of novel therapies. The continuous influx of new product launches is reshaping the competitive scenario, fostering an environment ripe for growth and development. Companies are strategically positioning themselves to capture emerging opportunities by leveraging advanced research and development capabilities. This momentum is further propelled by strategic collaborations and partnerships aimed at enhancing therapeutic efficacy and expanding market reach. In the competitive arena, key players are engaging in rigorous benchmarking to maintain their competitive edge. Regulatory influences play a pivotal role, with stringent guidelines dictating market entry and sustainability. The global landscape is characterized by a diverse regulatory framework, with North America and Europe setting stringent benchmarks that influence global standards. Asia-Pacific is emerging as a lucrative market, driven by favorable regulatory reforms and increased healthcare investments. The interplay of competition and regulation shapes the trajectory of the Cancer Immunotherapy Market, offering a fertile ground for innovation and growth.

Geographical Overview:

The cancer immunotherapy market is flourishing globally, with notable regional distinctions. North America leads, driven by substantial R&D investments and a high prevalence of cancer cases. The region's advanced healthcare infrastructure and robust biotech industry further propel market growth. Europe follows, with strong governmental support for cancer research and increasing adoption of innovative therapies. The region's focus on personalized medicine enhances its market position. In Asia Pacific, rapid expansion is observed, fueled by rising cancer incidences and growing healthcare expenditures. Countries like China and India emerge as key growth pockets, investing heavily in biotechnology and healthcare advancements. Latin America and the Middle East & Africa present promising opportunities. In these regions, increasing awareness and improving healthcare systems foster growth. Brazil and South Africa, in particular, are witnessing significant investments in cancer treatment infrastructure, recognizing the potential of immunotherapy in improving patient outcomes. These emerging markets are poised for substantial expansion in the coming years.

Key Trends and Drivers:

The Cancer Immunotherapy Market is experiencing robust growth fueled by technological advancements and increased investment in research and development. Key trends include the development of personalized immunotherapies tailored to individual patient profiles, enhancing treatment efficacy. The rise of combination therapies is another significant trend, offering improved outcomes by integrating multiple modalities. Furthermore, the expanding understanding of tumor microenvironments is driving innovation in targeted therapies. Increased regulatory support and expedited approval processes are accelerating market entry for novel treatments. Drivers include the growing prevalence of cancer worldwide and the unmet need for more effective therapies. Additionally, the market is benefiting from heightened awareness and acceptance of immunotherapy among healthcare providers and patients. Opportunities abound in emerging markets where healthcare infrastructure is improving, and demand for advanced treatments is rising. Companies investing in cutting-edge technologies and strategic collaborations are well-positioned to capitalize on these trends, ensuring sustained growth in the Cancer Immunotherapy Market.

Restraints and Challenges:

The cancer immunotherapy market encounters several significant restraints and challenges. One primary challenge is the high cost of treatment, which limits accessibility for many patients and places a financial burden on healthcare systems. These therapies often require substantial investment in research and development, leading to elevated prices. Regulatory hurdles also pose a significant challenge. The rigorous approval processes for new immunotherapies can delay market entry and increase costs. Furthermore, the complexity of cancer immunotherapy mechanisms makes it difficult to predict patient responses, leading to variable treatment outcomes. Another challenge is the limited availability of biomarkers for patient selection. This limits the ability to identify individuals who would benefit most from specific therapies, reducing treatment efficacy. Additionally, the market faces competition from traditional cancer treatments, such as chemotherapy and radiation, which are more established and widely accepted. Finally, there is a need for better public and professional awareness. The lack of understanding about immunotherapy's potential benefits can hinder its adoption and integration into standard care practices.

Key Players:

Adaptimmune Therapeutics, Immunocore, Iovance Biotherapeutics, Fate Therapeutics, Kite Pharma, Jounce Therapeutics, Replimune Group, Compugen, Agenus, OncoSec Medical, CureVac, Neon Therapeutics, BioNTech, Tessa Therapeutics, Argenx

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Mode
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Checkpoint Inhibitors
    • 4.1.3 Cancer Vaccines
    • 4.1.4 Cytokines
    • 4.1.5 Adoptive Cell Therapy
    • 4.1.6 Oncolytic Virus Therapy
    • 4.1.7 Bispecific Antibodies
    • 4.1.8 Immune Checkpoint Modulators
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Immune System Modulators
    • 4.2.3 Cell Therapies
    • 4.2.4 Checkpoint Blockade
    • 4.2.5 Cancer Vaccines
    • 4.2.6 Oncolytic Viruses
    • 4.2.7 Cytokines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Gene Editing
    • 4.3.2 CRISPR
    • 4.3.3 CAR-T Cell Therapy
    • 4.3.4 TCR Therapy
    • 4.3.5 Monoclonal Antibody Technology
    • 4.3.6 Nanotechnology
    • 4.3.7 Bi-specific Antibody Technology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Lung Cancer
    • 4.4.2 Breast Cancer
    • 4.4.3 Colorectal Cancer
    • 4.4.4 Melanoma
    • 4.4.5 Prostate Cancer
    • 4.4.6 Leukemia
    • 4.4.7 Lymphoma
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Cancer Research Institutes
    • 4.5.3 Clinics
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Academic and Research Institutes
  • 4.6 Market Size & Forecast by Mode (2020-2035)
    • 4.6.1 Intravenous
    • 4.6.2 Oral
    • 4.6.3 Subcutaneous
    • 4.6.4 Intramuscular
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Clinical Trials
    • 4.7.2 Commercialized
    • 4.7.3 Preclinical
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Immune Activation
    • 4.8.2 Immune Suppression
    • 4.8.3 Immune Modulation
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Personalized Immunotherapy
    • 4.9.2 Combination Therapies
    • 4.9.3 Targeted Therapy

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Mode
      • 5.2.1.7 Stage
      • 5.2.1.8 Functionality
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Mode
      • 5.2.2.7 Stage
      • 5.2.2.8 Functionality
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Mode
      • 5.2.3.7 Stage
      • 5.2.3.8 Functionality
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Mode
      • 5.3.1.7 Stage
      • 5.3.1.8 Functionality
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Mode
      • 5.3.2.7 Stage
      • 5.3.2.8 Functionality
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Mode
      • 5.3.3.7 Stage
      • 5.3.3.8 Functionality
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Mode
      • 5.4.1.7 Stage
      • 5.4.1.8 Functionality
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Mode
      • 5.4.2.7 Stage
      • 5.4.2.8 Functionality
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Mode
      • 5.4.3.7 Stage
      • 5.4.3.8 Functionality
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Mode
      • 5.4.4.7 Stage
      • 5.4.4.8 Functionality
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Mode
      • 5.4.5.7 Stage
      • 5.4.5.8 Functionality
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Mode
      • 5.4.6.7 Stage
      • 5.4.6.8 Functionality
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Mode
      • 5.4.7.7 Stage
      • 5.4.7.8 Functionality
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Mode
      • 5.5.1.7 Stage
      • 5.5.1.8 Functionality
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Mode
      • 5.5.2.7 Stage
      • 5.5.2.8 Functionality
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Mode
      • 5.5.3.7 Stage
      • 5.5.3.8 Functionality
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Mode
      • 5.5.4.7 Stage
      • 5.5.4.8 Functionality
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Mode
      • 5.5.5.7 Stage
      • 5.5.5.8 Functionality
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Mode
      • 5.5.6.7 Stage
      • 5.5.6.8 Functionality
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Mode
      • 5.6.1.7 Stage
      • 5.6.1.8 Functionality
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Mode
      • 5.6.2.7 Stage
      • 5.6.2.8 Functionality
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Mode
      • 5.6.3.7 Stage
      • 5.6.3.8 Functionality
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Mode
      • 5.6.4.7 Stage
      • 5.6.4.8 Functionality
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Mode
      • 5.6.5.7 Stage
      • 5.6.5.8 Functionality
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Adaptimmune Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Immunocore
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Iovance Biotherapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Fate Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Kite Pharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Jounce Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Replimune Group
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Compugen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Agenus
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 OncoSec Medical
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 CureVac
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Neon Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 BioNTech
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Tessa Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Argenx
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us